Cargando…

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis

BACKGROUND: For patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), the efficacy and safety of novel P2Y(12) antagonists, including prasugrel or ticagrelor, has not been established relative to that of the clopidogrel-based triple-ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhe, Zhou, Da-Yan, Su, Yong, Si, Liang-Yi, Xu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066764/ https://www.ncbi.nlm.nih.gov/pubmed/32164560 http://dx.doi.org/10.1186/s12872-020-01403-6

Ejemplares similares

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-naïve patients undergoing elective percutaneous coronary intervention
por: Habibi, Zarina, et al.
Publicado: (2023)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

Assessment of myocardial salvage in patients with STEMI undergoing thrombolysis: ticagrelor versus clopidogrel
por: Petousis, Stylianos, et al.
Publicado: (2022)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI
por: Türker, Yasin
Publicado: (2016)

Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome
por: Chen, Yunxian, et al.
Publicado: (2022)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
por: Olechowski, Bartosz, et al.
Publicado: (2016)

The Effect of Ticagrelor on Endothelial Function Compared to Prasugrel, Clopidogrel, and Placebo: A Systematic Review and Meta-Analysis
por: Guan, Baoyi, et al.
Publicado: (2022)

An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel
por: Joo, Seung-Jae, et al.
Publicado: (2015)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early?
por: Masiero, Giulia, et al.
Publicado: (2020)

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017
por: Rezaei, Safoura Sheikh, et al.
Publicado: (2020)

Absence of platelet membrane glycoproteins IIb/IIIa from monocytes
Publicado: (1985)

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
por: Kaluski, Edo
Publicado: (2008)

Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta‐analysis
por: Chen, Wenwen, et al.
Publicado: (2021)

Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics
por: Bauer, Timm, et al.
Publicado: (2010)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
por: Kim, Yuri, et al.
Publicado: (2023)

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
por: Suwaidi, Jassim Al, et al.
Publicado: (2001)

The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma
por: Kim, Seo-Hee, et al.
Publicado: (2021)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both?
por: Silva, Matthew A, et al.
Publicado: (2006)

Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry
por: Khayata, Mohamed, et al.
Publicado: (2017)

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
por: Kumar, Arun, et al.
Publicado: (2022)

Antiplatelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel
por: KIRKBY, N S, et al.
Publicado: (2011)

Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis
por: Hahn, JongSung, et al.
Publicado: (2023)

Ticagrelor is Not Superior to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI: A Report from Swedish Coronary Angiography and Angioplasty Registry
por: Völz, Sebastian, et al.
Publicado: (2020)

Comparison of Systematic Ticagrelor-Based Dual Antiplatelet Therapy to Selective Triple Antithrombotic Therapy for Left Ventricle Dysfunction Following Anterior STEMI
por: Bastiany, Alexandra, et al.
Publicado: (2018)

Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
por: Iannetta, Loredana, et al.
Publicado: (2013)

Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases
por: Abdeladim, Salma, et al.
Publicado: (2021)

Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
por: Kitazono, Takanari, et al.
Publicado: (2018)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial
por: Schnorbus, Boris, et al.
Publicado: (2021)

Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke
por: Lee, John-Ih, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_epfr65njdlflhsheng61ju058p